SOUTH MIAMI, Fla.--(BUSINESS WIRE)--OrganaBio is thrilled to announce the launch of NeoPAC™ placenta and umbilical cord tissues, its latest suite of products designed to accelerate the progress of regenerative medicine and cell therapy. By offering both Research Use Only (RUO) and clinical (cGMP) grade tissues, OrganaBio empowers researchers to tap into the potential of birth tissues, enabling the development of innovative therapies to address a wide range of medical conditions.
NeoPAC™ tissues from OrganaBio hold immense promise for mitigating or even curing various medical conditions, including hematological disorders, autoimmune diseases, tissue regeneration, neurological disorders, cancers, wound healing, GVHD, and more. With these best-in-class tissue offerings, researchers gain access to a powerful resource that has the potential to transform patient outcomes and revolutionize the field of medicine.
OrganaBio prioritizes delivering products of the highest quality, sourced with ethics and compliance at the forefront. Stringent protocols, which are IRB-approved, are adhered to throughout donor consent and qualification, as well as the tissue collection and processing stages. This commitment to excellence ensures that researchers receive clinically relevant materials for their scientific investigations, ultimately driving advancements in medical research and patient care.
“Access to a robust and reliable source of starting materials for tissue engineering, cell therapy, and immunotherapy continues to be a critical bottleneck for the regenerative medicine industry. The addition of the NeoPAC tissue line to our portfolio of birth tissue-derived cellular starting materials and peripheral blood products allows therapeutics developers more flexibility in working with OrganaBio. From donor recruitment and testing to product manufacturing and characterization, we customize each element to meet each of our customers’ unique needs. The launch of the NeoPAC product line further demonstrates our commitment to moving quickly to respond to industry needs around access to high quality biological materials, and with inherent flexibility built into the product offering,” said Dr. Priya Baraniak, Chief Business Officer of OrganaBio.
NeoPAC tissues offered by OrganaBio are meticulously collected from healthy donors at the time of birth, from c-section and non-c-section deliveries, through its wholly owned subsidiary, GaiaGift. To learn more about GaiaGift, please visit http://www.gaiagift.com. Researchers have the flexibility to choose from RUO tissues for preclinical research use or cGMP tissues for clinical applications, depending on their specific programmatic needs. Tissues are provided in both fresh and frozen formats.
For additional information and to place an order, please contact Dr. Carlos Carballosa, Director of Birth Tissue Product Sales, at carlos@organabio.com.
OrganaBio’s NeoPAC™ birth tissues represent a significant milestone in the field of regenerative medicine and cell therapy. By harnessing the potential of these tissues, researchers can unlock new possibilities in medical treatments, leading to improved healthcare outcomes and transforming the lives of patients worldwide.
About OrganaBio:
OrganaBio is a robust and reliable biotech solutions provider for cell therapy and immunotherapy developers. OrganaBio has opened doors to a new Contract Technology Development and Manufacturing Organization (CTDMO) paradigm that involves a passionate commitment to ethically accelerating the deployment of cell therapies through making accessible, critical resources that are essential for therapeutics development. The company’s products and services span the full development lifecycle – from proprietary tissue supply chains and cellular starting materials (e.g. MSCs (Mesenchymal Stromal Cells), HSCs (Hematopoietic Stem Cells), NK (Natural Killer) cells, T cells, etc.) to expert development, testing, and other support services that expedite the path to clinical translation within our state-of-the-art, ready-to-use cGMP manufacturing facility, enabling the rapid and economical manufacture of clinical materials.
OrganaBio believes in a paradigm where new CTDMO partnerships are needed to support a variety of organizations with a common mindset – one to accelerate the deployment of advanced therapies from its pre-clinical stages to scaling up towards global commercialization. OrganaBio’s commitment to provide access to these critical resources essential for therapeutic development ensures our partners are given the flexibility and agility to significantly reduce manufacturing cost and timelines through our state-of-the-art donor management facilities and remain committed to a culture of ethically sourcing raw materials from healthy donors, fully consented under IRB-approved protocols and in accordance with US (United States) FDA (Food and Drug Administration) 21 CFR 1271.
Looking for more information? Let us chat! https://www.organabio.com/contact/
